BRANFORD, Conn., April 17, 2015 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in providing cloud-based Pharma big data solutions for discovering novel products, today announced a poster presentation at the 106th Annual Meeting of the American Association for Cancer Research (AACR), to be held April 18-22, 2015 in Philadelphia, Pennsylvania. The presentation will highlight information supporting the expanded use of Big Data Analytics tools such as the Company's PharmGPS™ platform to identify novel immune checkpoints through improved understanding of key signaling pathways, their cross-talk with immune regulators, protein expression profile in tumor tissues, and patient outcomes.
Details of the presentation are as follows:
Abstract #64 (Poster #5) - Targeting immune checkpoints: using a big data approach for their identification, prioritization and application
- Poster Session: PO.MCB10.01. Computational Tools / Genomic Profiling of Tumors
- Date, Time, Location: Sunday, April 19; 1:00 – 5:00 p.m. ET; Section 3
Krishnan Nandabalan, Ph.D., President and CSO of BioXcel, said, "The AACR Annual Meeting is one of the cornerstone events in the oncology arena, and we are proud that our abstract has been accepted for presentation. Identifying novel immune checkpoints is a crucial step toward the development of new, targeted cancer therapies. The identification of such checkpoints, however, requires comprehensive analysis of large volumes of data covering a wide range of tumor and immune system characteristics, their correlations and potential impact on patient outcomes. Using PharmGPS™, we are able to effectively synthesize and analyze this unstructured data using a combination of natural language processing and 'pathway matrix analysis' to identify first, second and third degree associations between tumorigenic pathways and immune checkpoints. To-date, we have identified a number of immune checkpoints that demonstrate clear therapeutic potential across multiple solid tumor cancer types. We look forward to presenting this data to members of the oncology community at AACR, and to further exploring the potential of PharmGPS™ with our Pharma partners."
PharmGPSTM Oncology and Immuno-Oncology Suite
A live and multi-dimensional platform, BioXcel's proprietary suite enables the extensive analysis of solid tumors and hematological malignancies, and the impact of constituent global drug pipelines and benchmarking, novel drug targets and therapeutic approaches, including the inhibition of immune checkpoints, on standards of care and lines of therapies. All key drivers necessary for designing the most optimal combination therapies, clinical trial design and positioning of the right anti-cancer agents are taken into account to maximize market share and most importantly benefit to the patient. Furthermore, the suite is comprehensive in assessing all modalities, combinations of therapies and different stages of development. This extensive analysis delineates an optimal path with respect to indication segment relevance, best-fit therapies, and target effectiveness compared to the most relevant standard of care.
About BioXcel:
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages: PharmGPS™ - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and an executive team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
BioXcel Corporation Kartik Srinivasan Head of Marketing Email: The Ruth Group for BioXcel Lee Roth (Investors) / Iman Oubou (Media) Email: / Tel: 646 536 7012 / 646 536 7029
